CN102907606B - Beta-glucan composition and application thereof - Google Patents
Beta-glucan composition and application thereof Download PDFInfo
- Publication number
- CN102907606B CN102907606B CN201210460788.5A CN201210460788A CN102907606B CN 102907606 B CN102907606 B CN 102907606B CN 201210460788 A CN201210460788 A CN 201210460788A CN 102907606 B CN102907606 B CN 102907606B
- Authority
- CN
- China
- Prior art keywords
- beta
- test
- meal
- glucan
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a beta-glucan composition, which consists of the following raw materials in percentage by weight: 7.5 to 100 percent of beta-glucan powder, 0 to 30 percent of superfine carrot powder, 0 to 30 percent of superfine highland barley, 0 to 20 percent of erythritol, and 0 to 20 percent of isomaltooligosacharide. The composition has the functions of reducing blood fat and cholesterol, and the selected materials are medicinal and edible plants or plant extract, so that the beta-glucan composition is safe and non-toxic, can be eaten for a long time without toxic or side effect.
Description
Technical field
The present invention relates to health food processing technique field, relate in particular to a kind of beta-glucan composition and application thereof.
Background technology
Diabetes have become the chronic disease of the 3rd large serious threat human health after tumour, cardio cerebrovascular affection.At present there is 1.2 hundred million diabetic in the whole world, Chinese patients number row the second in the world, 20 years old above adult's onset diabetes rate up to 9.6%,, estimate to have reached 92,400,000 people.China also has a large amount of people in prediabetes (resistance to sugar amount is abnormal), accounts for 15.5%.The harm of diabetes is also various complication, and 1/2 IDDM patient and 2/3 patients with NIDDM have a kind of chronic complicating diseases of diabetes at least.Calendar year 2001 chronic complicating diseases investigation group of Chinese Medical Association's diabetology branch report in hospital type II diabetes complication illness rate is respectively: hypertension 34.2%, cranial vascular disease 12.6%, angiocardiopathy 17.1%, lower limb vascular disease 5.2%.The required medical expense of cardiovascular disease prevention is accounted for to topmost part in diabetes medical expense.The people such as Chen Xinbao were investigation in 2003, and the medical treatment cost for the treatment of type II diabetes has accounted for required expense 77.8% ~ 177.9%(different cities of annual income per capita).
The product in the market with hypoglycemic is many.Hypoglycemic medicine is divided into Western medicine and Chinese medicine, and hypoglycemic Western medicine is roughly divided into orally-taken blood sugar reducing medicine and injection hypoglycemic medicine.Wherein domestic conventional orally-taken blood sugar reducing medicine, take non-insulin class medicine as main, is divided into non-insulin class Drugs Promoting Insulin Secretion class, biguanides, alpha-glucosidase inhibitor class, insulin sensitizer at present.Wherein Drugs Promoting Insulin Secretion class is divided into again sulfonylureas and non-sulfonylureas (meglitinide).Injection hypoglycemic medicine is mainly take insulin and similar medicine thereof as main.This class medicine long-term taking side effect is larger, large on the impact of liver kidney, often causes nausea, the symptom such as vomiting, apocleisis, anorexia.
Hypoglycemic pcm common by diabetes pill, diabetes pill, clonidine capsule etc., this class Chinese patent drug is to come according to China's traditional medicine prescription, also has the active component that extracts from Chinese medicine, natural drug to make.This class medicine need to carry out medication according to different symptoms and physique, also has the symptom of nausea,vomiting,diarrhea etc. in the time of medication.
Conventional lipid lowerers is the special class of Statins, shellfish, nicotinic acid class, cholic acid chelating agent, the large class of cholesterol absorption inhibitor five, but these medicine long-term taking side effects are larger, common gastrointestinal reaction, nauseating, diarrhoea or constipation, headache, and severe patient can cause hepatic lesion.
02113578.9 1 kinds of hypoglycemics of Chinese patent ZL fat-reducing beans are take konjaku powder and soluble dietary fiber as primary raw material, add evening primrose oil, perilla oil and vitamin E, adopt the product of the sugared beans shape that conventional method makes.This invention is to utilize polydextrose in konjaku and the soluble dietary fiber effect at hypoglycemic.
Chinese patent ZL02139449.0 Tianqi sugar-reducing capsule is that the Radix Astragali, root of Chinese trichosanthes, the fruit of glossy privet, the stem of noble dendrobium, sun-dried ginseng, the root bark of Chinese wolf-berry, the coptis, Fructus Corni, eclipta, these processing of crude drugs of Chinese gall form.These compositions are medicinal plant entirely, belong to the antidiabetic drug of Chinese medicine class, long-term taking, and side effect is larger.
Chinese patent 200810181494.2 fat-eliminating antihypelipidemic health teas are to select lotus leaf, root of Chinese trichosanthes, raw hawthorn, reed rhizome, blue or green tea, lotus, rhizoma nelumbinis and gynostemma pentaphylla as raw material, through Preparation process, form.This invention is mainly to select to disappear the plant of lipid, accelerates fatty metabolism and discharge, utilizes selected plant to treat diabetes in the mode of the tonifying yin of promoting the production of body fluid.
A kind of soft capsule of making as raw material take avenabeta glucosan and linseed oil is provided in patent of invention 200910143155.X avenabeta glucosan capsule for descend of blood fat and preparation method thereof.This invention mainly has the effect that reduces T-CHOL removing triglycerides, simultaneously auxiliary hyperglycemic.
-glucan is a kind of functional polysaccharide being rich in grain cereal crops and microorganism wall.The research of modern medicine and nutrition show it have the immunity of organism of adjusting, anticancer, antitumor, reduce cholesterol, regulate the several functions such as blood fat and blood sugar.Beta glucan is mainly to extract from yeast, oat and barley at present.United states drug food control office and food security office of European Union meals, nutrition and irritated expert group are thought: 3 grams of beta glucans of every daily ingestion can be effectively hypoglycemic, reduce blood low-density lipoprotein and total blood cholesterol levels content, reduces the ill risk of cardiovascular and cerebrovascular disease.The extraction of cereal beta glucan is both at home and abroad mainly take oat as main, but Australia, the British Commonwealth are industrial, confirm with the clinical testing of the mechanism such as Science Institute, barley beta glucan than avenabeta glucosan reducing blood lipid, regulate aspect blood sugar even more ideal.In January, 2006, FDA determines that oat and barley equate for the effect that reduces Blood Cholesterol.Therefore conclude, eat the whole grain barley that contains β-glucan or the barley product that some dry method grinds, can contribute to reduce the concentration of Blood Cholesterol.So FDA is revising federal regulations code (CFR) the 21st and compiling the 101.81st part, the barley product that whole grain barley and some dry method are ground is included as the material that meets the dangerous Health Claims condition of soluble dietary fiber-heart disease.
Summary of the invention
Technical problem to be solved by this invention be to provide a kind of can be effectively hypoglycemic, reduce the beta-glucan composition of cholesterol effect.
Another technical problem to be solved by this invention is to provide this beta-glucan composition for the application of food, health food and medicine hypoglycemic, that reduce cholesterol.
For addressing the above problem, a kind of beta-glucan composition of the present invention, is characterized in that: said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5 ~ 100%, ultra micro carrot meal 0 ~ 30%, ultra micro highland barley flour 0 ~ 30%, antierythrite 0 ~ 20%, isomalto-oligosaccharide 0 ~ 20%.
Described beta glucan powder is from the one in yeast, oat, barley or the highland barley of mistake 60 ~ 120 mesh sieves, and beta glucan mass content >=20% wherein.
Described beta glucan powder is from the one in yeast, oat, barley or highland barley, and beta glucan mass content >=35% wherein.
One or more replacements for described ultra micro carrot meal in the balsam pear of ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, red date.
Described ultra micro is one or more replacements in corn, cocoa power, brown rice, brewer's yeast for highland barley flour.
A kind of beta-glucan composition as above, in the application of preparing in hypoglycemic, to reduce cholesterol food or health food or medicine, is characterized in that: contain this beta-glucan composition granulation electuary, tablet, chewable tablets or capsule according to a conventional method.
The present invention compared with prior art has the following advantages:
1, in the present invention, beta glucan is a kind of nutritional labeling inhibitor in nutrition, and contain multivitamin and trace element in the carrot of selection collocation and highland barley, make at edible beta glucan microelement-supplementing and vitamin simultaneously, made up the inhibition of separately edible beta glucan to Nutrient Absorption, in conjunction with the dietary fiber in carrot and highland barley, improve diabetic or prediabetes crowd stomach situation again simultaneously, improve its quality of the life, extend complication disease time.
2, carrot nutritional is worth and enriches, and comprises multiple carrotene, electrolytes and minerals etc., is therefore known as " common people's ginseng ".Long-term edible carrot can reduce body inner cholesterol content, strengthen immunologic function and the wide intestines defaecation anti-cancer of sharp diaphragm.The carrot meal using in the present invention is the Ultramicro-powder through low temperature dewatering and superfine communication technique production, this Ultramicro-powder has farthest retained the nutriment of carrot, and reached the granularity of breaking-wall cell, greatly increased the speed that nutritional labeling is dissolved in water.
3, the selected material of the present invention is plant or the plant extracts of integration of drinking and medicinal herbs, and safety non-toxic can eat for a long time, has no side effect.
4, selected beta glucan, carrot meal, highland barley flour and carrot meal and the alternative powder of highland barley flour of the present invention all has hypoglycemic effect, and four have synergy, and effect is more obvious than single use beta glucan.
5, the present invention tests through reality, has effect hypoglycemic, reducing blood lipid.
(1) experimenter selects
At 15 ~ 65 years old age, selection state of an illness after diet control or OHA treatment is more stable, does not need to change types of drugs and dosage, only takes the adult II diabetic of maintenance dose, fasting blood-glucose >=7.8mmol/L or postprandial blood sugar >=11.1mmol/L; Also can select the hyperglycemia population of 7.8mmol/L >=fasting blood-glucose >=6.7mmol/L or 11.1mmol/L >=fasting blood-glucose >=7.8mmol/L.
Experimenter can not be: IDDM (insulin-dependent) patient; Age is at under-18s or over-65s, gestation or loner (referring to diet control person in accordance with regulations); Through B ultrasonic, Chest X-rays and Electrocardioscopy, there are the complication such as the serious heart, liver, kidney, serious enterogastric diseases, or be associated with other serious primary disease persons, mental patient; Within nearly 3 months, there are Diabetic ketosis, DKA and the infected; Take glucocorticoid and the frequent pharmacohistory person who uses other influences blood sugar; Take in a short time the article relevant with tested function, have influence on the judgement person to result; Do not meet inclusive criteria, do not use in accordance with regulations given the test agent, cannot fat fourth effect and not umbra sound effect or security judgement person of data.
(2) experimental design
This experiment adopts double blind random grouping, between group and self two kinds of control design.According to above-mentioned Standard Selection trial volunteer, according to experimenter's blood sugar level, be divided at random test-meal group and control group, consider that as far as possible the factor that affects result is as the course of disease, the kind of taking medicine (sulfonylureas and biguanides), sex, age etc.Carry out harmony test, to guarantee the comparativity between group.
Before experiment to each experimenter by sex, age, different labor intensity, ideal body weight, with reference to original habits and customs, stipulate corresponding diet, each group of duration of test is adhered to diet control, former constant by drug kinds and dosage.Experimenter is by every day 3 times, and the dosage of each 1 bag particle electuary (specification: 4.5 grams/bag) is taken 60 days continuously.
The component of particles used electuary: beta glucan powder 58%, ultra micro highland barley flour 22%, ultra micro carrot meal 15%, antierythrite 5%, molecular clock monoglyceride 2.8 ‰, acesulfame potassium 1.5 ‰.After testing, in this formula, the content of beta glucan is 23.2%.
(3) detect index
After initial sum 60 days, (when research finishes) experimenter detects fasting blood-glucose, the variation of 2 hours blood glucoses, glucose in urine and blood fat after the meal, also adds up the variation of experimenter's clinical symptoms simultaneously.
(4) statistical procedures
The poor expression of mean ± criterion numeral for data result, self paired data adopts paired t-test, between test-meal group and control group under the prerequisite of homogeneity of variance, mean relatively adopts t check in groups, otherwise adopt t check after carrying out meeting homogeneity of variance after variable conversion, if variance is appointed so uneven, adopt rank test.The efficient X that presses
2check.
(5) result
1. Symptom Observation: in Table 1,2, take tested material 60 days, before test-meal group clinical symptoms integration and self experiment and control group comparison, difference has conspicuousness (P < 0.05).Test-meal group clinical observation total effective rate is (72.55%), has conspicuousness (P < 0.05) with control group (23.53%) comparing difference.
Table 1 clinical symptoms integration statistics (
± S)
Before note: * and test-meal, compare P < 0.05; # and control group be P < 0.05 relatively.
Table 2 clinical symptoms are improved situation
Note: # and control group be P < 0.05 relatively.
2. fasting blood-glucose
In Table 3, test-meal group fasting blood-glucose and control group comparison before test-meal, no significant difference (P > 0.05).After control group test-meal, the front comparing difference of fasting blood-glucose and test-meal is without conspicuousness (P > 0.05).After the test-meal of test-meal group, before fasting blood-glucose and test-meal, self relatively with after test-meal compares, difference has conspicuousness (P < 0.05), after test-meal, test-meal group fasting blood-glucose fall is 1.84 ± 0.58, with control group comparison (0.08 ± 0.56), difference has conspicuousness (P < 0.05).After the test-meal of test-meal group, fasting blood-glucose declines 19.81%.
Fasting blood-glucose variation before and after table 3 test-meal (mmol/L,
± S)
Before note: * and test-meal, compare P < 0.05; # and control group be P < 0.05 relatively.
3. postprandial blood sugar
In Table 4, test-meal group postprandial blood sugar and control group comparison before test-meal, no significant difference (P > 0.05).After control group test-meal, the front comparing difference of postprandial blood sugar and test-meal is without conspicuousness (P > 0.05).After the test-meal of test-meal group, before postprandial blood sugar and test-meal, self relatively with after test-meal compares, difference has conspicuousness (P < 0.05), after test-meal, test-meal group postprandial blood sugar fall is 1.87 ± 0.60, with control group comparison (0.05 ± 0.82), difference has conspicuousness (P < 0.05).After the test-meal of test-meal group, fasting blood-glucose declines 14.24%.
Postprandial blood sugar variation before and after table 4 test-meal (mmol/L,
± S)
Before note: * and test-meal, compare P < 0.05; # and control group be P < 0.05 relatively.
4. glucose in urine
In Table 5, before and after glucose in urine test self more suddenly between group relatively all without obvious change (P > 0.05), point out this composition to have no significant effect glucose in urine.
The variation of glucose in urine before and after table 5 test-meal (integrated value,
± S)
5. blood fat
Two groups of cholesterol (CHOL), triglycerides (TG), the horizontal situation of change of HDL (HDL-C) in Table 6, table 7, table 8.Before test, control group and test-meal group change of serum C HOL, the comparison of TG level, no significant difference (P > 0.05), has comparativity between pointing out two groups.After the test-meal of test-meal group, before CHOL, TG and test-meal, compare, difference has conspicuousness (P < 0.05), after the test of test-meal group, after CHOL, TG and control group test, compare, before and after test-meal, HDL-C level has no obvious change (P > 0.05).
Change of serum C HOL, TG, HDL-C level before and after table 6 test-meal
Change of serum C HOL, TG, HDL-C level before and after table 7 test-meal test
Before note: * and test-meal, compare relatively P < 0.05 of P < 0.05 # and control group
Change of serum C HOL, the horizontal situation of change of TG, HDL-C before and after table 8 test-meal test
6. security detects: body weight, blood pressure, heart rate, routine blood test, routine urinalysis (except glucose in urine), stool routine examination, biochemical indicator and bad reaction observation etc.
Edible tested material 60 days, two groups of experimenter's body weight, blood pressure, heart rate, routine blood test, routine urinalysis (except glucose in urine), stool routine examination, the every detection of biochemical indicator are all in normal range (NR).During test-meal, do not find obvious adverse reaction.Illustrate tested material to body health without obvious damage.
7. conclusion
Adopt counter point between own control note group, select the trial volunteer who meets experimental condition to take tested material 60 days, adhere to during this time keeping on a diet, former treatment diabetes medicament and dosage are constant.Result shows: the composition of this invention is improved effect to diabetes main clinic symptoms, and total effective rate is that 72.55%(control group is 23.53%); Before and after the test-meal of test-meal group fasting blood-glucose, self compares and control group comparison, difference all has conspicuousness (P < 0.05), test-meal group fasting blood-glucose fall and control group comparison, difference has conspicuousness (P < 0.05), and fasting blood-glucose test-meal group test-meal front and back are compared with declining 19.81% before test-meal; Before and after the test-meal of test-meal group postprandial blood sugar, self compares and control group comparison, difference all has conspicuousness (P < 0.05), test-meal group postprandial blood sugar fall and control group comparison, difference has conspicuousness (P < 0.05), and empty stomach test-meal group after the meal test-meal front and back are compared with declining 14.24% before test-meal.Illustrate that this composition has the effect of auxiliary hyperglycemic.
After the test-meal of test-meal group before CHOL, TG and test-meal relatively, difference all has conspicuousness (P < 0.05), and before CHOL, TG and test-meal, declines more respectively 17.75%, 25.87% after test-meal; Test-meal group CHOL, TG and control group comparison after test-meal, difference all has conspicuousness (P < 0.05); After test-meal, test-meal group HDL-C and control group comparing difference are without conspicuousness (P > 0.05).Illustrate that this composition has the effect of auxiliary antilipemic.
Two groups of front and back of test-meal experimenter's body weight, blood pressure, heart rate, routine blood test, routine urinalysis (except glucose in urine), stool routine examination, the every detection of biochemical indicator are all in normal range (NR).During test-meal, do not find obvious adverse reaction.Illustrate tested material to body health without obvious damage.
The specific embodiment
embodiment 1a kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 100%.
Wherein: beta glucan powder is from the yeast of crossing 60 ~ 120 mesh sieves, and beta glucan mass content >=20% wherein.
embodiment 2a kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5%, ultra micro carrot meal 30%, ultra micro highland barley flour 30%, antierythrite 20%, isomalto-oligosaccharide 12.5%.
Wherein: beta glucan powder is from the oat that crosses 60 ~ 120 mesh sieves, and beta glucan mass content >=35% wherein.
embodiment 3a kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 20%, ultra micro carrot meal 20%, ultra micro highland barley flour 30%, antierythrite 10%, isomalto-oligosaccharide 20%.
Wherein: beta glucan powder is from the barley that crosses 60 ~ 120 mesh sieves, and beta glucan mass content >=40% wherein.
embodiment 4a kind of beta-glucan composition, said composition is comprised of the raw material of following weight ratio: beta glucan powder 50%, ultra micro carrot meal 10%, ultra micro highland barley flour 20%, antierythrite 10%, isomalto-oligosaccharide 10%.
Wherein: beta glucan powder is from the highland barley that crosses 60 ~ 120 mesh sieves, and beta glucan mass content >=60% wherein.
Above-mentioned
embodiment 1 ~ 4in one or more replacements in the balsam pear of ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, red date for ultra micro carrot meal; Ultra micro is one or more replacements in corn, cocoa power, brown rice, brewer's yeast for highland barley flour.
Above-mentioned
embodiment 1 ~ 4in beta-glucan composition hypoglycemic in preparation, reduce application in food or health food or the medicine of cholesterol and refer to and contain this beta-glucan composition granulation electuary, tablet, chewable tablets or capsule according to a conventional method.
Claims (4)
1. a beta-glucan composition, is characterized in that: said composition is comprised of the raw material of following weight ratio: beta glucan powder 7.5 ~ 50%, ultra micro carrot meal 10 ~ 30%, ultra micro highland barley flour 20 ~ 30%, antierythrite 10 ~ 20%, isomalto-oligosaccharide 10 ~ 20%; Described beta glucan powder is from the one in yeast, oat, barley or the highland barley of mistake 60 ~ 120 mesh sieves, and beta glucan mass content >=20% wherein.
2. a kind of beta-glucan composition as claimed in claim 1, is characterized in that: one or more replacements for described ultra micro carrot meal in the balsam pear of ultra micro, pumpkin, green tea, konjaku, hawthorn, ginkgo leaf, PORIA ALBA, lotus leaf, Chinese yam, red date.
3. a kind of beta-glucan composition as claimed in claim 1, is characterized in that: described ultra micro is one or more replacements in corn, cocoa power, brown rice, brewer's yeast for highland barley flour.
4. a kind of beta-glucan composition as claimed in claim 1, in the application of preparing in hypoglycemic, to reduce cholesterol food or health food or medicine, is characterized in that: contain this beta-glucan composition granulation electuary, tablet, chewable tablets or capsule according to a conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460788.5A CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460788.5A CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102907606A CN102907606A (en) | 2013-02-06 |
| CN102907606B true CN102907606B (en) | 2014-04-16 |
Family
ID=47606369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210460788.5A Active CN102907606B (en) | 2012-11-16 | 2012-11-16 | Beta-glucan composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102907606B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405397A (en) * | 2013-08-30 | 2013-11-27 | 林宁 | Capsule located in bioadhesive drug delivery manner for releasing beta glucosan |
| CN104432037B (en) * | 2014-11-24 | 2016-03-30 | 广州市香雪制药股份有限公司 | Oxidation-resisting health-care alimentation composition and preparation method thereof and application |
| CN107232610A (en) * | 2017-05-25 | 2017-10-10 | 杭州特悘衡康生物科技有限公司 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
| CN107156851A (en) * | 2017-06-01 | 2017-09-15 | 四川惠泰农业科技有限公司 | Blood fat reducing health products containing beta glucan and preparation method thereof |
| CN107950864A (en) * | 2017-11-21 | 2018-04-24 | 北京工商大学 | A kind of symphysis unit paddy vegetable meal replacement powder and its preparation method and application |
| CN112656768A (en) * | 2019-10-16 | 2021-04-16 | 天士力医药集团股份有限公司 | Traditional Chinese medicine concentrated pill and preparation method thereof |
| CN114145457A (en) * | 2021-12-10 | 2022-03-08 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969674A (en) * | 2006-11-30 | 2007-05-30 | 吴江中怡实业有限公司 | Food additive |
| CN101991786A (en) * | 2009-08-28 | 2011-03-30 | 江春艳 | Formula of medicine for reducing blood fat and preparations thereof |
| CN101816449B (en) * | 2010-05-07 | 2013-01-02 | 西藏天麦力健康品有限公司 | Highland barley composite nutrition stiff paste drink and preparation method thereof |
-
2012
- 2012-11-16 CN CN201210460788.5A patent/CN102907606B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102907606A (en) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102907606B (en) | Beta-glucan composition and application thereof | |
| CN103099089B (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN105077236B (en) | Compound special meals nutrient powder of the highland barley of auxiliary hyperglycemic and preparation method thereof | |
| CN106983052A (en) | A kind of solid beverage of auxiliary hyperglycemic and preparation method thereof | |
| CN106666312A (en) | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof | |
| CN105211853A (en) | Blood sugar reducing health composition, electuary and preparation method thereof | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN102511710B (en) | Low energy nutrition powder | |
| CN102919836A (en) | Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof | |
| CN104146259B (en) | A kind of health-care flour for diabetic and preparation method thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102293273A (en) | Health tea capable of adjusting blood pressure, blood sugar and blood fat and preventing thrombus and apoplexy | |
| CN102763884A (en) | Health-care beverage of guava and making method of health-care beverage | |
| CN106692297A (en) | Composition for assistedly decreasing blood sugar, and preparation method and application thereof | |
| CN101756244A (en) | Functional food applicable to diabetic population | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN103734392A (en) | Fructus cannabis-black tartary buckwheat tea health beverage and preparation method thereof | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN102422957A (en) | Bawei danshen tea and preparation process thereof | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN102613453A (en) | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application | |
| CN105795263A (en) | Health beverage for enhancing immunity and regulating human body functions and preparation method thereof | |
| CN103637190A (en) | Functional food for prevention and treatment of diabetes and its preparation method | |
| CN107568375A (en) | A kind of adlay slim tea and preparation method thereof | |
| CN110623263A (en) | Traditional Chinese medicine meal replacement porridge and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 851400 No. 11, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region Patentee after: Tibet Qizheng Highland Barley Health Technology Co., Ltd. Address before: 850032 No. 189 Jinzhu West Road, Lhasa City, Tibet Autonomous Region Patentee before: Tibet Tianmaili Health Food Co., Ltd. |